Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive symbols : Azn save search
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Published: 2024-04-02 (Crawled : 08:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.18%
H: 0.34%
C: -0.22%
breast her2 license cancer application negative
ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors
Published: 2024-01-29 (Crawled : 11:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.24%
H: 0.07%
C: -0.1%
enhertu her2 granted review tumors positive
AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data
Published: 2023-12-12 (Crawled : 15:30) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 5.03%
H: 0.0%
C: -3.82%
ICVX | $15.31 -0.65% 9.3M
|
|
| O: 53.48%
H: 1.02%
C: 0.26%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.54%
H: 0.06%
C: -0.78%
vaccine astrazeneca positive acquire rsv potential
Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
Published: 2023-10-23 (Crawled : 19:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.57%
H: 1.06%
C: 0.36%
breast her2 cancer trial negative
Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
Published: 2023-09-22 (Crawled : 09:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 2.01%
H: 0.2%
C: -0.79%
breast her2 cancer trial negative
Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting
Published: 2023-05-25 (Crawled : 21:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: -0.02%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 3.65%
H: 7.04%
C: 1.02%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.06%
H: 0.48%
C: -0.04%
reqorsa lung asco positive cancer cell meeting trial therapy
Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
Published: 2023-02-16 (Crawled : 14:00) - globenewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -2.87%
H: 0.88%
C: 0.88%
FBIO | $1.765 -2.49% -2.55% 190K
|
Health Technology
|
| O: 0.81%
H: 5.54%
C: 3.66%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -2.65%
H: 1.22%
C: 0.16%
cibmtr trial positive therapy
ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03
Published: 2022-12-07 (Crawled : 15:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.45%
H: 0.64%
C: -0.03%
enhertu risk breast positive cancer her2- her2 metastatic breast cancer
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03
Published: 2022-12-07 (Crawled : 14:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.45%
H: 0.64%
C: -0.03%
enhertu risk breast cancer her2- her2 metastatic breast cancer
Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders
Published: 2022-11-08 (Crawled : 14:20) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 2.49%
H: 0.0%
C: -1.6%
FBIO | $1.765 -2.49% -2.55% 190K
|
Health Technology
|
| O: 0.0%
H: 4.76%
C: -4.6%
ATXI | $0.1295 -3.79% -3.94% 320K
|
Health Technology
|
| O: 7.78%
H: 6.67%
C: -7.78%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.2%
H: 0.96%
C: 0.18%
treatment acquisition system therapeutics positive
ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer
Published: 2022-08-15 (Crawled : 09:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.92%
H: 0.22%
C: -0.65%
enhertu treatment disease trial positive cancer her2- her2 metastatic breast cancer
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
Published: 2022-05-05 (Crawled : 12:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.35%
H: 0.4%
C: -1.2%
enhertu approved cancer breast cancer her2- her2 metastatic breast cancer
ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
Published: 2022-05-05 (Crawled : 10:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.35%
H: 0.4%
C: -1.2%
enhertu approved positive cancer breast cancer her2- her2 metastatic breast cancer
Artelo Biosciences Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia
Published: 2022-04-13 (Crawled : 13:00) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -3.19%
H: 3.22%
C: 0.54%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.04%
H: 0.84%
C: 0.57%
ARTL | $1.28 -1.94% 5.5K
|
Health Technology
|
| O: 38.1%
H: 27.29%
C: -12.83%
pre-clinical program positive art27.13 preclinical cancer
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
Published: 2022-01-17 (Crawled : 09:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
| Email alert
Add to watchlist
enhertu granted positive cancer breast cancer her2- her2 metastatic breast cancer
ENHERTU® Additional Analyses Further Reinforce Groundbreaking Efficacy in Patients with HER2 Positive Metastatic Breast Cancer
Published: 2021-12-09 (Crawled : 19:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.27%
H: 0.63%
C: -0.58%
enhertu positive cancer breast cancer her2- her2 metastatic breast cancer
DESTINY-Breast11 Neoadjuvant Phase 3 Trial of ENHERTU® Initiated in Patients with High-Risk HER2 Positive Early-Stage Breast Cancer
Published: 2021-11-30 (Crawled : 14:30) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.7%
H: 0.0%
C: 0.0%
risk trial positive cancer phase 3 breast cancer initiated her2- her2
TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Published: 2021-11-18 (Crawled : 21:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.46%
H: 0.33%
C: -0.32%
positive cancer phase 3 breast cancer trial initiated hormone her2+ her2- her2 metastatic breast cancer
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.